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The present investigation concerns the development of mucoadhesive tablets of Captopril 
which were designed to prolong the gastric residence time after oral administration. 
Matrix tablets of Captopril were formulated using different mucoadhesive polymers 
such as guar gum, xanthan gum, hydroxyl propyl methyl cellulose K4M and K15M in 
various ratios. The tablets were evaluated for physical properties, content uniformity, 
swelling index, bioadhesive strength and in-vitro drug release. Swelling was increased 
as the concentration and viscosity of HPMC increases. Tablets formulated using guar 
gum and xanthan gum alone were eroded faster and dissolved completely within 
5-7 hr, while tablet containing HPMC remain intact and provided slow release up to 
11-12 hr. It was evident from the study that the formulation F10 containing HPMC 
K15M and xanthan gum (1:1) exhibited maximum bioadhesive strength of 31.59±0.05 
gm and in vitro drug release was found to be 91.85 % at the end of 12 hr with non-
fickian diffusion mechanism. The stability studies of optimized batch showed that there 
was no change in bioadhesive strength and in-vitro release when stored at different 
temperature condition for 60 days. It was concluded that formulation F10 shows the 
better bioadhesive strength and drug release.
KEYWORDS: Captopril, Gastro-retentive tablet, Mucoadhesive tablets, Swelling Index.
RESUMEN
El estudio actual trata del desarrollo de los comprimidos mucoadhesivos de captopril, 
que se diseñaron con el fin de prolongar el tiempo de permanencia gástrica después 
de la administración oral. Se formularon matrices de comprimidos de captopril 
mediante diferentes polímeros mucoadhesivos, tales como goma guar, goma xantana, 
hidroxipropilmetilcelulosa K4M y K15M, a varias concentraciones. Los comprimidos 
se evaluaron según sus propiedades físicas, uniformidad del contenido, índice de 
inflamación, fuerza de bioadhesión y liberación farmacológica in vitro. La inflamación 
se incrementó cuando la concentración y la viscosidad de HPMC aumentaron. Los 
comprimidos formulados solamente con goma guar y goma xantana se descompusieron 
con mayor rapidez y se disolvieron completamente en un rango de 5-7 horas, mientras 
que los comprimidos con HPMC permanecieron intactos y mostraron una liberación 
lenta de hasta 11-12 horas.  Se observó que la formulación F10 con HPMC K15M y 
goma xantana (1:1) tenía una fuerza bioadhesiva máxima de 31,59±0,05 g y la liberación 
farmacológica in vitro fue del 91,85%, al final de un periodo de 12 horas con un 
mecanismo de difusión no de Fick. Los estudios de estabilidad de lotes optimizados 
mostraron que no hay cambios en la fuerza bioadhesiva y la liberación in vitro cuando se 
mantiene bajo condiciones de diferentes temperaturas durante 60 días. Se concluyó que 
la formulación F10 presenta la mejor fuerza bioadhesiva y liberación farmacológica.
PALABRAS CLAVE: Captopril, Comprimido gastro-retentivo, Comprimidos 
mucoadhesivos, Índice de inflamación. 
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INTRODUCCIÓN
One of the novel approaches for drug delivery system is 
Gastro-retentive delivery system (GRDS). Prolonging the 
gastric retention of a delivery system are desirable for 
achieving therapeutic benefit of drugs that are absorbed 
from the proximal part of the gastrointestinal tract (GIT) 
or that are less soluble in GIT or are degraded by the 
alkaline.1,2 GRDS are thus beneficial for such drugs by 
improving their bioavailability, therapeutic efficacy and 
by possible reduction of dose.3 Park and Robinson et al., 
had first introduce the term “Bioadhesion”. Bioadhesive 
polymers are platforms for oral controlled drug delivery 
method to study bioadhesion has been studied extensively 
in the last decade and applied to improve the performance 
of these drug delivery systems.4
Mucoadhesive controlled release dosage formulations 
have gained considerable attention due to their ability 
to adhere to the mucus layer and release the drug in a 
sustained manner. The relevant routes of mucoadhesive 
formulations have involved nasal, gastrointestinal, buccal, 
ocular, vaginal and rectal ways. By using these dosage 
forms, the intimate contact time with the mucus surface 
would increase, thus resulting in an increased drug 
retention time and drug concentration in the local sites. 
This would lead to an improved therapeutic effect for 
the local diseases.5,6 Mucoadhesive delivery systems offer 
several advantages over other oral controlled release (CR) 
systems by virtue of prolongation of residence time of 
drug in GIT, and targeting and localization of the dosage 
form at a specific site.7 Mucoadhesive polymers are able to 
interact with mucus which is secreted by the underlying 
tissue. More specifically, it is predicted that such polymers 
interact with mucus glycoprotein, called mucins, which 
are responsible for gel-type characteristics of the mucus. 
Mucoadhesive polymers can increase the contact time with 
the mucosal tissue and moreover, also increase directly 
drug permeability across epithelial barriers.8,9
Captopril, an antihypertensive agent, has been widely used 
for the treatment of hypertension and congestive heart 
failure. Captopril is acid stable and completely absorbed 
in gastric pH. It has been reported, that the duration of 
antihypertensive action after a single oral dose of Captopril 
is only 6–8 h, biological half life is 2-3 h and bioavailability 
in the stomach is 60- 75%. The pKa value is 4.5. Hence, as 
the pH increases, it becomes unstable and undergoes a 
degradation reaction and thus reducing its bioavailability.10-12 
Water-soluble drugs are considered difficult to deliver in 
the form of sustained or controlled release preparation due 
to their susceptibility to ‘‘dose dumping phenomenon.’’ 
Attempts have been made to regulate their release process 
by use of mucoadhesive polymers in order to achieve a 
once-a-day dose treatment.13
The current study aims at developing and evaluating oral 
mucoadhesive drug delivery system of Captopril, as it may 
prove to be more productive than the conventional CR 
systems by virtue of prolongation of drug residence time 
in GI tract. Captopril exhibits pH dependant degradations 
and is more stable in acidic pH compared to neutral or 
alkaline pH conditions. Hence, an attempt was made to 
develop mucoadhesive tablets of Captopril which would 
increase the bioavailability of Captopril. The prepared 
tablets were evaluated for physical properties (thickness, 
weight variation, friability and hardness), swelling index, 




Captopril BP (Macleods Pharmaceutical Ltd.), HPMC K4M 
and HPMC K15M (Colorcon Asia, Goa, India), Xanthan 
gum, guar gum and Avicel PH-102 (Signet Chemical Corp., 
Mumbai, India), PVP K-30, Dicalcium Phosphate (DCP), 
Talc I.P. and Magnesium stearate I.P. (Loba Chemie, 
Mumbai, India) were received as gift sample.
Preparation of Mucoadhesive Tablets
Mucoadhesive tablets of Captopril were prepared by wet 
granulation technique using different concentrations of 
HPMC K4M, HPMC K15M, Xanthan gum and Guar gum. 
All the ingredients were passed through sieve no 85# and 
were mixed uniformly. Granulation was carried out with 
sufficient quantity of binder solution (PVP K 30 - 5% in 
isopropyl alcohol).  Wet mass was passed through sieve 
no 12# and dried at 45-55oc for 2 hr. Dried granules were 
sized by sieve no. 18# and add Avicel PH 102, magnesium 
stearate and talc. Granules obtained were compressed 
with 9mm flat punch (Cadmach, Ahmedabad, India). The 
formulations are shown table 1.14
Evaluation of Mucoadhesive tablets
Physical parameters
Tablets were tested for hardness, friability, weight variation 
and drug content. Hardness of the tablets was tested using 
a Monsanto hardness tester and Friability of the tablets was 
determined in a Roche friabilator (Model EF2, Electrolab, 
Mumbai, India).15
Swelling index
Initial weight (W1) of tablet was carried out and placed it in 
a beaker containing 200 ml of HCl buffer (pH 1.2). After each 
interval time the tablet was removed from beaker, remove 
excess water and blotted with filter paper to remove the 
32
Dalvadi HP, Patel JK, Rajput GC, Muruganantham V, Jayakar B.
Ars Pharm. 2011; 52(2): 31-37.
Ars Pharm. 2011; 52(2): 31-37.
Table 1. Formulae of Captopril Mucoadhesive Tablets.
All the quantities are in mg.
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excess of water 16. Then the device immediately weighed 
and again introduce in to the same beaker, and note down 
the weight (W2) and was performed up to 8 hr. The swelling 
index was calculated using following formula.  
Swelling index = (W2 – W1) / W1  (1)
In Vitro (ex vivo) evaluation of bioadhesion
Bioadhesion studies were conducted, using a modification 
of the assembly described earlier, with porcine gastric 
mucosa as the model membrane. The mucosal membrane 
was excised by removing the underlying connective and 
adipose tissue, and equilibrated at 37°C ± 1°C for 30 min 
in PBS before the bioadhesion evaluation study. The tablet 
was lowered on to the mucosa under a constant weight of 
5 g for a total contact period of 1 min. Bioadhesive strength 
(f) was assessed in terms of the weight in grams required to 
detach the tablet from the membrane.17
Tablet bioadhesion is assessed by detachment tests 
measured between the tablet and a substrate to which it 
has been previously applied. Many of these types of tests 
have been described with different substrates and means 
of measuring the detachment forces. Though artificial 
substrates have been studied, typically the substrate is a 
mucosa. A mucosa should be chosen which is similar to that 
at the intended site of adherence of the tablet. The tablet 
and mucosa are wetted then put into contact for a given 
time to allow interpenetration of the polymer chains and 
adhesion to develop. Detachment is typically in the vertical 
direction and the force is measured via a balance.18
In vitro drug release studies
Dissolution studies of all batches were performed employing 
USP XXIII paddle-type dissolution test apparatus (Model 
TDL-08, Electrolab, Mumbai, India) using 900 ml HCl buffer 
(pH 1.2) as dissolution medium at 50 rpm and 37°C ± 0.5°C. 
A 5-mL aliquot of the sample was withdrawn periodically 
at suitable time intervals and the volume replaced with an 
equivalent amount of the dissolution medium. The samples 
were analyzed spectrophotometrically at 209 nm using UV 
Visible Spectrophotometer (Shimadzu, UV 1601). Drug 
release experiments were conducted in triplicates.
Stability study
Optimized batch of Captopril tablets (Formulation F10) 
were kept for a short term stability study in high density 
polyethylene sealed cover at 40 ± 2 ºC / 75 ± 5% RH as 
per ICH Guidelines. Samples were withdrawn for Six week 
and 3 month of storage and evaluated for appearance, drug 
content, bioadhesive strength and in vitro dissolution.
RESULT AND DISCUSSION 
It was desirable to deliver such drug in a gastro retentive 
dosage form or mucoadhesive drug delivery systems 
which would prolong the gastric residence time of drug 
delivery thereby giving sufficient time for drug delivery 
system to release the drug and efficient absorption of active 
moiety. It was suggested that mucoadhesive drug delivery 
system are easiest approach for technical and logical point 
of view among gastro retentive drug delivery system, so 
for present study mucoadhesive drug delivery system was 
chosen.19,20
Mucoadhesive tablets were evaluated for its physical 
characteristics; the results are shown in Table 2. Hardness 
of the tablets was found in the range of 6.57 ± 0.400 - 7.53 
± 0.451 kg/cm2. Percentage weight loss in the friability test 
was found to be 0.41 % in all batches. Content uniformity 
of all the prepared batches is within the limit (Captopril 
100 ± 3 % of the labeled content). We can conclude that all 
the batches of tablets prepared were of good quality with 
regard to hardness, friability and drug content. 
Initially, tablets were formulated employing mucoadhesive 
polymer guar gum alone, it was observed that the tablets 
were eroded faster and completely dissolved in 4-5 hr. 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
Captopril 100 100 100 100 100 100 100 100 100 100 100
Guar gum 50 100 - - - - - - - -
Xanthan gum - - 50 100 - - - - - 50 50
HPMC K4M - - - - 50 100 - - 50 - 50
HPMC K15M - - - - - - 50 100 50 50 -
PVP K-30 20 20 20 20 20 20 20 20 20 20 20
Dicalcium Phosphate (DCP) 54 04 54 04 54 04 54 04 04 04 04
Talc 3 3 3 3 3 3 3 3 3 3 3
Mg. stearate 3 3 3 3 3 3 3 3 3 3 3
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So, tablets were prepared using xanthan gum and HPMC 
mucoadhesive polymers. It was found that the tablets were 
intact over a period of 12 hr; this may be due to the high gel 
forming nature of HPMC and Xanthan gum.
In Vitro (ex vivo) evaluation of bioadhesion
Many research articles have been published presenting 
with slightly different theories and mechanisms of 
mucoadhesion. The reason for this disagreement is may 
be not so surprising because there have been so many 
different in vivo and in vitro methods utilized to measure 
mucoadhesive properties of polymers, resulting in 
inconsistent results. 
The mucoadhesive property of Captopril tablets, alone 
or combination of xanthan gum and HPMC K15M grade 
polymer were determined with modified balance. Results 
are shown in Table 3. Several studies have demonstrated 
that the bioadhesiveness of tablets depends on the rate of 
swelling and initial contact time.
It was observed that polymer mixtures showed higher 
adhesion and higher water uptake. The highest adhesion 
force i.e. highest strength of the mucoadhesive bond 
(31.59±0.05 gm) was proposed by F10 containing HPMC 
K15M and Xanthan gum (1:1) in combination with total 
polymer concentration is 40%. The mixture Xanthan 
gum:HPMC K15M 1:1 showed good in vitro mucoadhesion 
compared to  mixture HPMC K4M : HPMC K15M and 
xanthan gum : HPMC K4M.
It was concluded that as the concentration of polymer 
increases, mucoadhesive strength increases and viscosity 
of polymer also affect the mucoadhesive strength.
The ex vivo bioadhesion results illustrate the positive effect 
of contact time and contact force on work of adhesion. This 
Batch Code Weight Variation (mg) Hardness (kg/cm2) Thickness (mm) Friability (%) Drug content (%)
F1 240.3±5.12 6.83±0.289 3.033±0.11 0.57 98.56
F2 240.8±3.95 6.63±0.321 2.80±0.05 0.58 99.43
F3 239.9±4.09 6.57±0.401 2.76±0.05 0.55 97.12
F4 239.8±4.23 7.20±0.263 2.70±0.15 0.39 98.76
F5 240.2±2.89 6.77±0.250 2.66±0.05 0.41 99.96
F6 240.1±2.78 7.53±0.451 2.93±0.15 0.49 98.51
F7 240.3±2.05 6.43±0.494 2.55±0.08 0.61 99.84
F8 239.9±2.22 7.07±0.502 2.62±0.05 0.76 98.39
F9 240.0±2.10 7.10±0.458 2.53±0.052 0.67 99.78
F10 239.8±2.39 6.60±0.173 2.81±0.076 0.48 97.01
F11 240.5±2.11 6.70±0.200 2.76±0.115 0.39 98.45
Table 2. Formulae of Captopril Mucoadhesive Tablets.
Each reading is an average of three determinations (Avg.± S.D)












Table 3. In-vitro Mucoadhesive strength for all 
formulated batches
aEach reading is an average of three determinations 
(Avg.± S.D)
is predicted by the diffusion theory of Mucoadhesion, 
which requires interpenetration and entanglement of the 
polymer chains with mucus chains. The bond strength 
increases as the degree of interpenetration increases with 
contact time and contact force. 
Swelling Study
Swelling study was performed for all the batches up to 8 
hr. The results of swelling index are shown in Fig. 1. The 
batches contains HPMC K15M (F8) had more swelling 
because of its higher viscosity as compared to batches 
contains HPMC K4M (F6). In the present study, the 
higher swelling index was found for tablets of batch F10 
containing HPMC K15M having 15,000 cps viscosity. We 
can also conclude that the viscosity of the polymer had 
major influence on swelling process, matrix integrity, as 
well as adhesion capability.  Hence, it can be concluded 
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Figure 1. Water uptake study of mucoadhesive tablets at different time 
interval.
from the results that linear relationship 
exists between swelling process and 
bioadhesion of polymer. 
It was also observed that the maximum 
swelling was attained in 7 hr, after 
words polymer slowly started erosion 
in the medium. The high initial uptake 
of water may be due to the faster 
hydration rate of HPMC K15M. It was 
also observed that the swelling rate 
increased with an increase in HPMC 
content of the tablets. 
In-vitro Dissolution Study
The In-vitro drug release profiles 
of Captopril are shown in Fig. 2 
and 3. The In-vitro release study 
showed satisfactory sustained release 
of Captopril from all medicated 
formulae. Xanthan gum and HPMC 
are hydrophilic swellable polymer 
matrices; they are able to form a 
viscous gel layer; which controls the 
drug release via diffusion through the 
gel and erosion of the gel barrier.
It was observed that as there was a 
reduction in the amount of the polymer 
to the half ensures faster release. This 
may be attributed due to the reduction 
of the strength of the gel layer, which 
enhances drug diffusion and water 
uptake through the matrix. It was 
concluded from the results that as there 
was increases in polymer concentration 
of HPMC the release of drug might be 
slower. This is also supported by Xu 
and Sunada who reported that HPMC 
content was predominant controlling 
factor.21
The cumulative % release of batch F1 
and F2 were found to be 97.61% in 5hrs 
and 96.22% in 7 hrs respectively. The 
cumulative % release of batch F3 and 
F4 were found to be 93.34% in 7 hrs and 
94.32 % in 9 hrs respectively.
The cumulative % release of batch F5 
and F6 were found to be 94.89% in 8 
hr and 98.07 % in 9 hr, respectively. It 
was observed that the release is less as 
compared to Xanthan gum polymer. 
This may be because it’s a high viscosity. 
Figure 3. Drug Release profile of Captopril mucoadhesive tablets (Batches 
F9 to F11).
Figure 2. Drug Release profile of Captopril mucoadhesive tablets (Batches 
F1 to F8).
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The cumulative % release of batch F7 and F8 were found to 
be 96.65% in 9 hr and 97.79 % in 11 hr, respectively. 
While using blends of polymers in different batches like 
Batch F9 (HPMC K4M and HPMC K15M in 1:1 ratio), Batch 
F10 (Xanthan gum and HPMC K15M in 1:1 ratio), and 
Batch F11 (Xanthan gum and HPMC K4M in 1:1 ratio), the 
cumulative % release of batch F9, F10 and F11 were found 
to be 90.20% in 12 hr, 91.85% in 12 hr and 97.79 % in 11 hr, 
respectively. 
Finally, it was concluded from dissolution profile of 
different batches that the drug release rate was decreased 
as the concentration of polymer increases and also affect 
the type of polymer used. This can probably be attributed 
to the different diffusion and swelling behaviors of the 
polymer. With the increasing macromolecular weight, the 
degree of entanglement of the polymer chains increases. 
Thus the mobility of the macromolecule in the fully swollen 
systems decreases. 
It was also conclude that the release rate was decreased 
when the viscosity and/or concentration of the polymer 
was increased. The linear relationship was found between 
the viscosity of the polymer and release rate of drug from 
the drug delivery system.
Analysis of the drug release data
Method of Bamba and Puisieusx  was adopted for study of 
kinetics of drug release for the most appropriate model. The 
dissolution data of all batches were fitted to zero-order, first-
order, Higuchi, Hixson-Crowell, Korsemeyer and Peppas, 
and Weibull models.22. The results of regression coefficient 
were used for the selection of the most appropriate model. 
The release profile of the best batch F10 fitted best to 
Korsemeyer and Peppas (R2 = 0.9981), showing the least 
residual sum of square as compared to Higuchi (R2 = 
0.9811) and zero-order equation (R2 = 0.9975) model. This 
superiority is however statistically insignificant among 
these three models as shown by the goodness of regression 
coefficient. Thus, it may be concluded that the drug 
release from hydrophilic matrix of Captopril tablets is best 
explained by Korsemeyer and Peppas model. The n-values 
obtained between 0.5188 to 0.789 for fitting the drug release 
data to the Peppas-korsmeyer equation, indicated that the 
drug release mechanism from these tablets was non-fickian 
diffusion controlled. 
Stability studies
The results stability studies are shown in table 5, it revealed 
that there was no significant change in appearance, and 
mucoadhesive strength for optimized batch F10. However, 
there was slight variation in In-vitro release of optimized 
batch (F10), when it was stored at room temperature and at 
40 ± 2 ºC/ 75 ± 5% RH for three months. It was concluded 
that tablets are stable after stability studies.
CONCLUSION 
The current study indicates that the hydrophilic matrix 
tablets of captopril, prepared using hydrophilic polymer 
like Xanthan Gum, HPMC K4M and HPMC K15M. The 
tablets exhibited good mucoadhesive properties in an in 
vitro test. Captopril release from these mucoadhesive 
tablets was slow and extended over longer periods of time. 
The Batch F10 mixture HPMC K15 M: Xanthan Gum (50:50) 
Showed good mucoadhesion. 
It may be concluded that mucoadhesive tablet of Captopril 
prepared using mucoadhesive polymer by wet granulation 
method seems to be the promising formulation, providing 















Table 4. Diffusion coefficient (n) and r values of 
various formulation of Captopril. 
R2:Regression coefficient; n: Release exponent.
Formulation
Parameters
Hardness (kg/cm2) Mucoadhesive strength (g)  Drug release (%)
After 6 week 6.50±0.173 31.585±0.041 89.86
After 12 week 6.50±0.5 31.55±0.049 89.15
Table 5. Stability study of optimized batch F10.
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bioavailability of drugs such as Captopril that undergo 
degradation in higher pH when administered orally.
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